What Are Peptides? Types, Benefits, and Uses in Medicine

What Exactly Is a Peptide?

A peptide is a molecule made of amino acids connected by peptide bonds. The body produces hundreds of them naturally, and they regulate nearly every physiological process, from blood sugar control to tissue repair. Peptides differ from proteins only by size: proteins contain more than 50 amino acid residues, while peptides contain fewer.

The Chemistry Behind Peptide Bonds

Each peptide bond forms through a condensation reaction between the carboxyl group of one amino acid and the amino group of the next. This covalent linkage creates a stable backbone. The specific sequence of amino acids determines the peptide's three-dimensional shape, which in turn dictates which receptor it binds and what biological effect it triggers 1.

Peptides vs. Proteins vs. Amino Acids

A single amino acid is a monomer. Two amino acids joined form a dipeptide. Chains of 2 to 50 amino acids are peptides. Anything longer is classified as a protein. This distinction matters clinically: peptides are small enough to bind specific receptors with high affinity yet large enough to carry meaningful biological instructions. Insulin, at 51 amino acids, sits right at the boundary and is sometimes classified as either 2.

The human body synthesizes over 7,000 known peptides. They function as hormones, neurotransmitters, growth factors, and antimicrobial agents. Synthetic versions of these molecules now form the basis of a therapeutic class that generated over $40 billion in global sales in 2023 alone 3.

Major Types of Peptides

Peptides group into functional categories based on their biological activity. Understanding these categories clarifies why a single drug class can treat conditions as different as obesity, chronic wounds, and immune deficiency. The diversity is enormous.

Hormone Peptides

These include insulin, glucagon, oxytocin, vasopressin, and the incretin hormones GLP-1 and GIP. Hormone peptides travel through the bloodstream to distant target organs. GLP-1, a 30-amino-acid peptide secreted by intestinal L-cells, stimulates insulin release, suppresses glucagon, and slows gastric emptying 4. Synthetic analogs of GLP-1 (semaglutide, liraglutide, tirzepatide) now represent the highest-revenue peptide drug class worldwide.

Neuropeptides

Neuropeptides act within the central and peripheral nervous systems. Endorphins, enkephalins, substance P, and neuropeptide Y fall into this group. They modulate pain perception, appetite, mood, and stress responses. Substance P, for example, is an 11-amino-acid peptide that transmits pain signals; drugs targeting its receptor (NK1 antagonists like aprepitant) are standard antiemetics in chemotherapy 5.

Antimicrobial Peptides

Also called host defense peptides, these molecules are part of the innate immune system. Defensins and cathelicidins kill bacteria, fungi, and enveloped viruses by disrupting microbial membranes. Human beta-defensin 2 expression increases during skin infections and intestinal inflammation. A 2021 review in Nature Reviews Drug Discovery identified over 30 antimicrobial peptides in clinical or preclinical development, targeting drug-resistant infections where conventional antibiotics fail 6.

Growth Factor and Signaling Peptides

This category includes peptides like GHK-Cu (a tripeptide that promotes collagen synthesis), BPC-157 (a 15-amino-acid fragment of gastric juice protein), and thymosin beta-4 (involved in tissue repair and angiogenesis). These peptides activate intracellular signaling cascades that regulate cell proliferation, migration, and extracellular matrix remodeling 7.

Opioid Peptides

Endorphins, dynorphins, and enkephalins bind to mu, kappa, and delta opioid receptors. They regulate pain and reward pathways. Beta-endorphin, a 31-amino-acid peptide released during exercise and stress, produces analgesia comparable to morphine at the receptor level. Synthetic opioid peptides have been explored as alternatives to traditional opioids, though abuse potential remains a concern 8.

How Peptide Drugs Work in the Body

Peptide therapeutics mimic, block, or amplify the action of naturally occurring peptides. Their mechanism depends on receptor binding. A peptide drug binds a cell-surface receptor, triggers a conformational change, and initiates a downstream signaling cascade that produces the therapeutic effect.

Receptor Specificity and Selectivity

Peptides bind their target receptors with high specificity because their three-dimensional structure must match the receptor's binding pocket precisely. This selectivity explains why peptide drugs tend to produce fewer off-target effects than small-molecule drugs. Dr. Tomi Sawyer, a peptide chemist and former president of the American Peptide Society, has noted: "Peptides occupy a unique therapeutic space between small molecules and biologics, offering antibody-like specificity at a fraction of the molecular weight" 9.

Pharmacokinetic Challenges

Native peptides degrade rapidly. The half-life of endogenous GLP-1 is approximately 2 minutes due to cleavage by dipeptidyl peptidase-4 (DPP-4). Drug developers overcome this limitation through several strategies: fatty acid acylation (semaglutide binds albumin, extending half-life to 7 days), PEGylation (adding polyethylene glycol chains), amino acid substitution (replacing L-amino acids with D-amino acids at cleavage sites), and cyclization (constraining the peptide backbone to resist enzymatic attack) 10.

These engineering approaches transformed peptides from laboratory curiosities into once-weekly or even once-monthly drugs. The difference between native GLP-1's 2-minute half-life and semaglutide's 168-hour half-life is entirely a product of molecular engineering.

FDA-Approved Peptide Drugs: A Clinical Survey

More than 80 peptide-based drugs hold FDA approval as of 2026. They span endocrinology, oncology, cardiology, immunology, and infectious disease. Three categories dominate current prescribing.

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound) are the most widely prescribed peptide drugs globally. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo 11. Tirzepatide, a dual GIP/GLP-1 receptor agonist, achieved up to 22.5% weight reduction in the SURMOUNT-1 trial (N=2,539) at the 15 mg dose 12.

Insulin and Glucagon Analogs

Insulin lispro, insulin aspart, insulin glargine, and insulin degludec are all peptide drugs. Glucagon (for hypoglycemia rescue) and pramlintide (an amylin analog for postprandial glucose control) extend this category. Collectively, insulin analogs remain among the most prescribed medications in the United States, with over 8.4 million Americans using some form of insulin therapy according to CDC data 13.

Growth Hormone Releasing Peptides

Tesamorelin (Egrifta), approved for HIV-associated lipodystrophy, stimulates growth hormone release via the GHRH receptor. In a 26-week trial, tesamorelin reduced trunk fat by 15.2% versus 0.5% with placebo 14. Sermorelin, an older GHRH analog, is used off-label for age-related growth hormone decline, though evidence for anti-aging benefits remains limited.

Peptides in Regenerative and Experimental Medicine

Beyond FDA-approved drugs, peptides are being studied for tissue repair, neuroprotection, and longevity. This is where clinical evidence ranges from strong to preliminary.

BPC-157

Body Protection Compound-157 is a 15-amino-acid synthetic fragment derived from human gastric juice. Animal studies show it accelerates tendon, ligament, muscle, and gut healing through upregulation of growth hormone receptor expression and nitric oxide pathways 15. No completed randomized controlled trials in humans exist. The FDA issued warning letters in 2023 to compounding pharmacies making specific therapeutic claims about BPC-157. Its legal status for clinical use remains unsettled.

Thymosin Alpha-1

Originally isolated from thymic tissue, thymosin alpha-1 (Zadaxin) is approved in over 35 countries for hepatitis B and as an immune adjuvant. It enhances T-cell maturation and dendritic cell function. A meta-analysis of 8 randomized trials found thymosin alpha-1 improved virological response rates in chronic hepatitis B by 10 to 15 percentage points over interferon alone 16.

MOTS-c and Humanin

These mitochondrial-derived peptides are among the newest entries in longevity research. MOTS-c, a 16-amino-acid peptide, improves insulin sensitivity and exercise capacity in animal models. Dr. Pinchas Cohen, Dean of the USC Leonard Davis School of Gerontology, described MOTS-c as "the first exercise-mimetic peptide derived from the mitochondrial genome" 17. Human trials are in early stages.

Safety Profile and Side Effects

Peptide drugs are generally well-tolerated because they mimic endogenous molecules. Side effects tend to be mechanism-based and dose-dependent rather than idiosyncratic.

GI Side Effects

Nausea, vomiting, and diarrhea are the most common adverse events across GLP-1 receptor agonists. In STEP-1, 44.2% of participants on semaglutide 2.4 mg reported nausea versus 17.4% on placebo 11. These effects typically peak during dose escalation and diminish within 4 to 8 weeks. Slow titration reduces severity.

Injection Site Reactions

Because most peptides require subcutaneous injection, local reactions (redness, swelling, mild pain) occur in 2 to 10% of patients depending on the drug and formulation. Rotating injection sites minimizes this risk 18.

Rare but Serious Risks

Medullary thyroid carcinoma has been observed in rodent studies of GLP-1 agonists at supratherapeutic doses. The FDA requires a boxed warning on all GLP-1 receptor agonists, though human epidemiological data from the SNAC registry and other surveillance databases have not confirmed elevated thyroid cancer risk at therapeutic doses 19. Pancreatitis occurs at a rate of approximately 0.1 to 0.3% per year in clinical trials of GLP-1 drugs.

How Peptides Are Administered

Route of administration directly affects a peptide's bioavailability, onset of action, and patient adherence. Most peptide drugs are injected, but oral and alternative delivery systems are expanding rapidly.

Subcutaneous Injection

This is the standard route for insulin, GLP-1 agonists, growth hormone peptides, and most investigational peptides. Subcutaneous tissue provides slow, sustained absorption. Autoinjector pens and prefilled syringes have simplified self-administration significantly.

Oral Peptide Delivery

Oral semaglutide (Rybelsus) broke a long-standing barrier. It uses a co-formulation with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), which enhances gastric absorption by raising local pH and inhibiting pepsin. Oral bioavailability remains low (approximately 0.4 to 1%), requiring a 14 mg oral dose to approximate the exposure of a 1 mg injected dose 20. Patients must take it on an empty stomach with no more than 4 oz of water, then wait 30 minutes before eating.

Nasal and Transdermal Routes

Nasal calcitonin (Miacalcin) has been available for osteoporosis for decades. Nasal oxytocin is used in research settings. Transdermal peptide delivery via microneedle patches is in clinical development for insulin and GLP-1 agonists, with phase II trials underway as of 2025 21.

Choosing a Peptide Therapy: What Clinicians Consider

Selecting the right peptide drug involves matching the patient's diagnosis, comorbidities, renal function, and insurance coverage to the available options. No single peptide addresses every condition.

Indication-Specific Selection

For type 2 diabetes with obesity, the 2024 American Diabetes Association Standards of Care recommend GLP-1 receptor agonists or dual GIP/GLP-1 agonists as preferred second-line agents after metformin, particularly in patients with established cardiovascular disease or a BMI above 27 22. For growth hormone deficiency confirmed by stimulation testing, tesamorelin or sermorelin may be appropriate. For chronic wound healing, peptide therapies remain investigational.

Cost and Access Barriers

List prices for branded GLP-1 agonists range from $900 to $1,350 per month without insurance. Compounded peptides from 503B pharmacies cost less but carry questions about purity and consistency. The FDA's enforcement actions against certain compounding pharmacies in 2023 and 2024 underscore the importance of sourcing peptide therapies from FDA-registered facilities only 23.

A typical starting point: confirm the diagnosis, verify insurance formulary coverage or cash-pay pricing, begin at the lowest effective dose, and titrate based on clinical response and tolerability at 4-week intervals.